RxDoctor Payments Data

Chad Boekes, MD

Family Medicine · Castle Rock, CONPI 1538245816

Payments from drug & device makers

$3,974in general payments, 2019–2025

Across 202 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$704
  • AbbVie$427
  • Amgen$317
  • Pfizer$312
  • Lilly USA, LLC$219
  • Novo Nordisk$198
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,91198%
  • Education$632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,974 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$128,884
Medicare patients
222
Services billed
1,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$67,557
TrulicityDulaglutide32$56,390
OzempicSemaglutide34$55,547
JanuviaSitagliptin Phosphate29$41,908
FarxigaDapagliflozin Propanediol28$34,227
XareltoRivaroxaban19$27,362
Repatha SureclickEvolocumab16$24,380
JardianceEmpagliflozin14$23,766
Janumet XrSitagliptin Phos/Metformin Hcl17$21,065
Spiriva RespimatTiotropium Bromide15$12,286
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$8,687
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,591
Ezetimibe283$5,644
SymbicortBudesonide/Formoterol Fumarate14$4,559
Advair HfaFluticasone Propion/Salmeterol11$4,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$312$67,55754 claims
MerckJanuvia, Janumet Xr$90$62,97346 claims
Lilly USA, LLCTrulicity$219$56,39032 claims
Novo NordiskOzempic$198$55,54734 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$704$47,37753 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$189$44,73941 claims
Johnson & JohnsonXarelto$103$27,36219 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$32$3,614373 claims
AbbVieSynthroid$427$3,57631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Castle Rock

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →